What Ardelyx, Inc. told the SEC could break it.

A major, realized reimbursement-policy risk: XPHOZAH (for hyperphosphatemia in CKD dialysis patients) became part of the Medicare ESRD Prospective Payment System (PPS) bundle and continues to lack Medicare Part D coverage, which Ardelyx states will result in a materially lower pace of revenue growth than before. The effect is already visible — XPHOZAH net product sales fell from $160.9 million in 2024 to $103.6 million in 2025. As a dialysis-focused drug, XPHOZAH's economics are tightly bound to CMS bundling/TDAPA and Part D policy. A material, realized U.S. reimbursement/regulatory exposure on a key product.

“the continued lack of Medicare Part D coverage for XPHOZAH will result in a materially lower pace of revenue growth as compared to expectations before XPHOZAH became part of the ESRD PPS”

Ardelyx depends on foreign CROs and CMOs, and flags that if these become subject to trade restrictions, sanctions, increased tariffs or other U.S. requirements — including designation as a 'biotechnology company of concern' under the U.S. BIOSECURE Act — or if the U.S. or Chinese government take retaliatory actions amid U.S.-China tensions, its supply chain and development/manufacturing could be materially harmed. This compounds its single-source CMO exposure with a geopolitical/trade-policy dimension. A distinctive U.S.-China biotech-decoupling/BIOSECURE-Act regulatory exposure.

“If the foreign CROs and CMOs we rely on become subject to trade restrictions, sanctions, increased tariffs or other regulatory requirements by the U.S. government (including designation as a “biotechnology company of concern” under the U.S. BIOSECURE Act), or if the U.S. or Chinese government take retaliatory actions due to recent or increased tensions between the U.S. and China”

Ardelyx relies on contract manufacturers (CMOs), many of which are single-source: three stages of its manufacturing process are currently completed by a single source, and it has no qualified alternative sources for these single-source CMOs. This exposes its supply of IBSRELA, XPHOZAH and tenapanor API (including API it must supply to partners like Kyowa Kirin) to delivery failure and drug shortages, and to CMO pricing adjustments tied to market prices. A disruption at a single-source CMO could halt supply until a costly, time-consuming requalification. Suppliers unnamed, so a sole-source/supplier-concentration risk.

“To date, we have no qualified alternative sources for these single source CMOs.”